New hope to stop aggressive head & neck Cancer's return
NCT ID NCT02841748
Summary
This study is testing whether a one-year course of an immunotherapy drug called pembrolizumab can help prevent cancer from returning in people with high-risk head and neck cancer. About 100 patients who have already finished their main cancer treatment will be randomly assigned to receive either the drug or a placebo. The main goal is to see if the drug helps patients live longer without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Emory University Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.